Idylla EGFR Mutation Test (CE-IVD)
A0060/6
Within 150 minutes and with less than 2 minutes hands-on time, the fully automated IdyllaTM EGFR Mutation Test covers 51 mutations in exons 18–21 in a single cartridge using only 1 FFPE tissue section from metastatic NSCLC showing a high concordance of >95% compared with reference methods.
For more information on the PlexZyme and PlexPrime license statements, click here,
Specimen requirements
One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. With the IdyllaTM System only a minimal amount of sample is needed
- 1x 5 μm FFPE tissue section
- Neoplastic cells ≥10% - if less, macrodissection is required
TESTIMONAL
In this recording, Dr Leo Tallafigo Moreno highlights "the importance of adequate diagnosis in lung cancer and the transformative impact of Idylla™ EGFR in thoracic oncology".1
This video presentation has been prepared by Dr Leo Tallafigo Moreno, who has received a fee from Biocartis NV for his contribution. The content is intended for educational purposes and reflects the personal views of the presenter. It has not been reviewed or modified by Biocartis NV. This video is sponsored by Biocartis NV. Please consult a healthcare professional for medical advice specific to your condition. The Idylla™ EGFR Mutation Test is validated for the use of FFPE tissue in metastatic NSCLC.
Testimonial
Today, EGFR testing is a cumbersome process and it often takes several weeks before results are analyzed. This may lead to the administration of anti-EGFR therapy as second-line agents, which is less efficient than their use in first-line therapy. The IdyllaTM EGFR Mutation assay technology has the potential to change that; it is a cost-effective solution, ensuring reliable and fast detection of all relevant mutations.
Prof Giancarlo Troncone
University of Napoli Federico II, Naples, Italy
